| metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | ||
| non squamous - mNSCLC - L1 - all population | non squamous - mNSCLC - L1 - Wild Type (WT) | |
| atezolizumab based treatment | ||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | IMpower-150 ... | IMpower-150 ... IMpower-150 ... |
| atezolizumab plus carboplatin plus nab-paclitaxel | IMpower-130 ... | IMpower-130 ... |
| atezolizumab plus carboplatin plus paclitaxel | IMpower-150 ... | |
| atezolizumab plus pemetrexed and platin | IMpower-132 ... | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
